Childhood Vascular Tumors Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (11/08/2018)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Benign Tumors

The Ophthalmologic involvement of hemangiomas subsection was renamed from Periorbital infantile hemangioma.

Added text to state that infantile hemangiomas can occur in the conjunctiva. These hemangiomas can be associated with other ophthalmologic abnormalities and are treated with oral or topical beta-blockers (cited Theiler et al. as reference 26).

Added text to state that pyogenic granulomas are usually cutaneous, but deep-seated/subcutaneous pyogenic granulomas are noted and mimic other vascular lesions (cited Putra et al. as reference 111).

Added text to state that a study of 22 patients with pyogenic granuloma who were treated with topical 1% propranolol ointment with occlusion found that 59% of patients achieved a complete response, 18% of patients had stable disease, and 22% of patients did not respond to the treatment. In this study, only skin toxicity was assessed. The authors did not comment on the penetrance of the propranolol formulation or include a safety evaluation of the side effects such as hypoglycemia and the effects on heart rate or blood pressure (cited Neri et al. as reference 114).

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Special Considerations for the Treatment of Children With Cancer

Next section >
About This PDQ Summary